I Spent 24 Years In Finance. Now I’m Focusing On Longevity Biotech.

DISCLAIMER: This newsletter is independent research and personal opinion, not financial or health advice. I am not a registered investment advisor, broker-dealer, or licensed financial professional. Nothing here is a recommendation to buy or sell any security. EverLife Capital Fund I is a simulated paper portfolio only. No actual fund exists and no capital is being managed for third parties. Investing in early-stage biotech is highly speculative and involves substantial risk including total loss of capital. Always consult a qualified financial professional before making any investment decision.

I turned 51 and something shifted.

Not a crisis. Nothing dramatic. Just a quiet, persistent clarity that arrived somewhere between the birthday and the weeks after it. The kind that comes when you finally stop being too busy to think. I had spent 24 years building CuraDebt, a debt settlement company with 1,600+ five star client reviews and had helped many people. We had an A+ BBB rating and were Accredited with the BBB. We had processes, systems, a team. I had poured most of my adult life into that business and I was proud of what we built.

But sitting with 51, I kept coming back to one question I had never seriously asked myself: how much time do I actually have left, and am I spending it on the right things?

That question is what eventually led me here.

I have a Computer Engineering degree from UC San Diego. I am not a scientist. I am not a doctor. What I am is someone who spent nearly a quarter century in financial services learning one lesson over and over in different forms: the story is always more compelling than the fundamentals, and the people who trust the story over the fundamentals eventually pay for it.

I watched this play out thousands of times in the debt settlement world. People who had made financial decisions based on optimistic narratives about their income trajectory, their real estate, their business, and found themselves on the other side of those decisions needing help. They were not foolish people. They were people who had trusted compelling stories without a systematic framework for evaluating them.

The lesson I internalized from 24 years of watching that pattern: processes beat hunches. Discipline beats enthusiasm. The systems you build before the decision are the only real protection you have when the emotional pressure to make exceptions is at its peak.

I took that lesson with me when I started paying serious attention to longevity biotech. It is the reason I built a 21-gate evaluation framework. And it is the reason I trust the framework when it tells me no, even when the story is compelling.

At 51, I started tracking my biological age seriously for the first time. I got an Oura ring, then Ultrahuman, did various bioage tests. I started looking at my biomarkers not as abstract health metrics but as a real-time report on how fast I was aging. And I did not like everything I saw.

More importantly, I started being honest with myself about the math. If average life expectancy is roughly 78 for men in the United States, and I am 51, that is not that far away. If I want to live differently, to live to 90, or 100, or the 120 I am actually aiming for, I cannot just hope for it. I have to do the work, and I have to do it now, while the science is still developing and while interventions that could genuinely change the trajectory of aging are still early enough to matter.

That personal reckoning changed how I think about almost everything. What I eat. How I move. How I sleep. What I read. And critically, what I feel is important for my time and attention professionally.

I had already been following longevity biotech for several years. But there is a difference between following a sector with intellectual curiosity and deciding that it is the most important thing you can be working on. The birthday made that difference concrete for me.

Here is what I believe, and I want to be direct about it: we are living through the early years of a genuine revolution in how human aging works. The biology of aging, the specific cellular and molecular mechanisms that drive the deterioration we associate with getting old, is now understood at a level of detail that was not possible 20 years ago. And that understanding is producing drug candidates that could, if they work, meaningfully change the trajectory of human healthspan.

Not for everyone. Not immediately. Not without the long, expensive, frequently humbling process of clinical development. But the direction is clear, and the pace is accelerating.

I also believe that most investors are not paying the right kind of attention to this sector yet. The complexity of the science keeps many people at a distance. The historical absence of a clear FDA pathway for aging as an indication has made institutional capital cautious. The result is that some of the most important early-stage companies in this space are still accessible at valuations that reflect genuine uncertainty rather than hype. That is exactly the condition under which the best returns are made.

That window will not stay open forever. The sector is maturing. Institutional capital is beginning to move. The time to build a deep, systematic understanding of these companies, and to take early positions in the best ones, is now, not after the next wave of approvals makes the opportunity obvious to everyone.

Every other investment category I have seriously studied offers one kind of return: financial. You allocate capital, the thesis plays out, you are wealthier or you are not.

Early-stage longevity biotech offers two. The financial return if the company succeeds. And the biological return, the real possibility that the technology you are backing could give you, and the people you love, more healthy time. More years of being capable and present and useful.

That second return is what makes this different from any other place I could put serious attention. At 52, having just sold part of the business I built over two decades, I am not looking for another way to accumulate financial returns for their own sake. I am looking for something that matters. Something where doing the work well has consequences that go beyond the portfolio.

This is that thing.

I have screened more than 290 longevity biotech companies over the last 10 years, through a systematic evaluation process I call the 21-Gate Framework. Every gate in the framework exists because the failure mode it catches has ended a real company in documented history. The framework covers leadership track record, capital structure, endpoint validation, competitive position, and the kill switch criteria that tell a board when to stop spending capital if the biology is not translating.

Each month in this newsletter, I publish big picture thesis commentaries such as this one as well as deep-dives of early-stage private or microcap public longevity biotech companies that I feel are noteworthy of analysis based on the 21-Gate Framework. I also publish ongoing updates on every company that has earned a position in the simulated portfolio as well as ones on the watch-list. 

I am not here to tell you what to buy. I am here to show you a process, a way of thinking, of analyizing, and let you evaluate both for yourself. If the framework is sound, the record will show it. If it is not, the record will show that too.

At 52, I have the personal motivation to care deeply about the outcome, and the analytical background to do this work rigorously. That combination feels like exactly the right foundation for this chapter.

I am glad you are here for it.

If you found this valuable, subscribe for industry commentaries and monthly deep-dives on early-stage and microcap longevity biotech companies screened through the full 21-Gate Framework.